Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy

Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer’s disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity. Nowadays, THA serves as a valuable scaffold for the d...

Full description

Bibliographic Details
Main Authors: Eva Mezeiova, Jan Korabecny, Vendula Sepsova, Martina Hrabinova, Petr Jost, Lubica Muckova, Tomas Kucera, Rafael Dolezal, Jan Misik, Katarina Spilovska, Ngoc Lam Pham, Lucia Pokrievkova, Jaroslav Roh, Daniel Jun, Ondrej Soukup, Daniel Kaping, Kamil Kuca
Format: Article
Language:English
Published: MDPI AG 2017-07-01
Series:Molecules
Subjects:
acetylcholinesterase
Alzheimer’s disease
butyrylcholinesterase
tacrine
7-MEOTA
huprine Y
2-methoxyhuprine
Online Access:https://www.mdpi.com/1420-3049/22/8/1265

Internet

https://www.mdpi.com/1420-3049/22/8/1265

Similar Items